CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action-Reference-Cited by-同舟云学术

CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action

Published:2020-05-27 Issue:13 Volume:24 Page:7239-7253
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cell Mol Med

Author:

Hu Cheng¹,Xia Hongyan¹,Bai Shanshan¹²,Zhao Jianlei¹,Edwards Holly³⁴,Li Xinyu¹,Yang Yanrong⁵,Lyu Jing¹,Wang Guan¹,Zhan Yang¹,Dong Yan²^ORCID,Ge Yubin³⁴^ORCID

Affiliation:

1. National Engineering Laboratory for AIDS Vaccine Key Laboratory for Molecular Enzymology and Engineering The Ministry of Education School of Life Sciences Jilin University Changchun China

2. Department of Structural and Cellular Biology Tulane University School of Medicine Tulane Cancer Center New Orleans LA USA

3. Department of Oncology Wayne State University School of Medicine Detroit MI USA

4. Molecular Therapeutics Program Barbara Ann Karmanos Cancer Institute Wayne State University School of Medicine Detroit MI USA

5. School of Nursing Jilin University Changchun China

Funder

Jilin Scientific and Technological Development Program

Projects of Jilin Province Science and Technology Development Plan

National Key R&D Program of China

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine